ClinicalIntelPulse

Live 402 challenge

Captured by the enrichment pass, not read just now. Prices can change — always read the 402 the endpoint answers with.

{
  "error": "X-PAYMENT header is required",
  "accepts": [
    {
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "extra": {
        "name": "USD Coin",
        "version": "2"
      },
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "scheme": "exact",
      "network": "base",
      "mimeType": "application/json",
      "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan",
      "description": "Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.",
      "maxAmountRequired": "150000",
      "maxTimeoutSeconds": 300
    }
  ],
  "x402Version": 1
}

Accepts

The payment requirements as published to the catalog. Read the live 402 before paying — a price here is a claim, not a quote.

[
  {
    "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "extra": {
      "name": "USD Coin",
      "version": "2"
    },
    "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
    "amount": "150000",
    "scheme": "exact",
    "network": "eip155:8453",
    "maxTimeoutSeconds": 300
  },
  {
    "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
    "extra": {
      "feePayer": "GVJJ7rdGiXr5xaYbRwRbjfaJL7fmwRygFi1H6aGqDveb"
    },
    "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
    "amount": "150000",
    "scheme": "exact",
    "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
    "maxTimeoutSeconds": 300
  }
]

Extensions

{
  "bazaar": {
    "info": {
      "input": {
        "type": "http",
        "method": "GET",
        "queryParams": {
          "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
          "phase": "phase2 | phase3 | both (default: both)",
          "status": "active | all (default: active — recruiting + active not recruiting)",
          "condition": "Disease or condition — e.g. \"Non-Small Cell Lung Cancer\" | \"Alzheimer Disease\" | \"Type 2 Diabetes\" | \"Crohn Disease\" | \"Multiple Myeloma\""
        }
      },
      "output": {
        "type": "json",
        "example": {
          "query_summary": {
            "condition": "Non-Small Cell Lung Cancer",
            "status_filter": "RECRUITING,ACTIVE_NOT_RECRUITING",
            "phases_searched": [
              "PHASE2",
              "PHASE3"
            ]
          },
          "pipeline_totals": {
            "phase2_count": 156,
            "phase3_count": 89,
            "total_active": 245
          },
          "phase3_highlights": [
            {
              "nctId": "NCT05116748",
              "title": "Pembrolizumab + Carboplatin vs SOC in NSCLC",
              "status": "RECRUITING",
              "sponsor": "Merck",
              "countries": [
                "United States",
                "Germany",
                "Japan",
                "South Korea"
              ],
              "primaryCompletion": "2026-03"
            }
          ],
          "sponsor_landscape": {
            "academic_sponsors": "ECOG-ACRIN, Alliance, NCI leading academic cooperative groups",
            "emerging_biotechs": [
              "Turning Point Therapeutics",
              "Blueprint Medicines",
              "Mirati Therapeutics"
            ],
            "top_industry_sponsors": [
              "Roche/Genentech (18 trials)",
              "Bristol-Myers Squibb (14)",
              "AstraZeneca (13)",
              "Merck (12)",
              "Pfizer (11)"
            ]
          },
          "mechanism_breakdown": {
            "adc": 18,
            "other": 81,
            "bispecific": 12,
            "targeted_therapy": 41,
            "chemo_combinations": 31,
            "io_checkpoint_inhibitors": 62
          },
          "pipeline_assessment": "Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.",
          "approved_drugs_context": "NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.",
          "geographic_distribution": {
            "asia_pct": 22,
            "other_pct": 5,
            "europe_pct": 28,
            "us_trials_pct": 45,
            "most_active_countries": [
              "United States",
              "China",
              "Germany",
              "South Korea",
              "Japan"
            ]
          }
        }
      }
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema"
    }
  },
  "builder-code": {
    "info": {
      "a": "bc_gxy6qn5p"
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema",
      "properties": {
        "a": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "App builder code"
        },
        "s": {
          "type": "array",
          "items": {
            "type": "string",
            "pattern": "^[a-z0-9_]{1,32}$"
          },
          "description": "Service builder codes"
        },
        "w": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "Wallet builder code"
        }
      },
      "additionalProperties": false
    }
  }
}

Provenance

Seen in the source catalog

2026-07-01 04:25Z

Last indexed by Roundhouse

2026-07-30 16:00Z

Last enriched (probe, favicon, geo)

2026-09-11 06:15Z

x402 version

2

Max timeout

300s

Liveness probe

HTTP 402